CD38 and Miyoshi myopathy: To assess the efficacy of SAR442257 in primary MM samples, we first characterized samples from NDMM (n = 100) and RRMM (n = 40) patients, including RRMM patients from three cohorts, as follows: cohort 1: refractory to anti-CD38 antibodies (n = 26); cohort 2: refractory to bispecific antibodies for TC engagement (n = 10); or cohort 3: ELO/POM (n = 4), for aberrant expression of CD28 on primary MM cells using mean fluorescence intensity (MFI) by flow cytometry (Figure 2a).